Contact this trialFirst, we need to learn more about you.
MAPK Pathway Inhibitor
DCC-3116 for Solid Tumors
Recruiting3 awardsPhase 1 & 2
New York, New York
This trial is testing a new drug, DCC-3116, as a possible treatment for advanced or metastatic solid tumors. The study will consist of two parts: a dose-escalation phase, where patients will receive increasing doses of the drug to test its safety, and an expansion phase, where patients will receive the drug in combination with other drugs to test its effectiveness.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.